Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$223.29 USD
-6.29 (-2.74%)
Updated May 28, 2024 04:00 PM ET
After-Market: $223.32 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 41 - 60 ( 184 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Liver Defatting Key to NASH Resolution - Fibrosis Reversal - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 8 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q19 - Do Not Miss Buying Ahead of OCA Approval - Sema Data - Must Read
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q Recap; Both Pivotal Studies to Complete Enrollment by YE21; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Forget to Dial-in to Our NASH Call Today with Dr. Arun Sanyal at 1PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our NASH Expert Call with Dr. Arun Sanyal Moved to Friday, Feb. 21, at 1PM ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Forget to Dial-in to Our Call Today with Dr. Arun Sanyal at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Join our Part 2 NASH Call on Feb. 18 with Dr. Arun Sanyal
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Do Not Miss Our NASH Fibrosis Call with Dr. Scott Friedman at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Dial In to Part 1 of Our Three-Part NASH Call Series Tomorrow at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Yas'' Weekly Recap of Our Key Notes and 12 Doc Calls Upcoming in 1H20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Revisit NASH in 2020: Join Our Three-Part Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from Our Doc Call with Dr. Seth Baum
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Yas'' Weekly Recap of Our Key Notes and 9 Doc Calls Upcoming in 1Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Join our Jan. 27 Call: Get Down to Resmetirom''s Brass Tacks in Reducing CV Risk
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare -Join Our 1Q20 Doc Call Series in PWS, NASH, Omega-3s and Contraception
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y